PubMed · 2025

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial

Browne SK, Suschak JJ, Tomah S, Gutierrez JA (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP reports : innovation in hepatology.

JHEP reports : innovation in hepatology

Source: https://pubmed.ncbi.nlm.nih.gov/41113119/

Last reviewed . By the PeptIQ team.

View original source
XRedditFacebook

Peptides linked in PeptIQ Wiki

    This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.